Jaipur

GPAT-2012 PAPER

{Answers are on the end page of question Paper}

Rajasthan Drugs & Pharmaceuticals Ltd (RDPL) is profit making Central Public Sector Enterprise. The The Company was formed as a joint venture between Central Government with 51% equity share holding and Rajasthan State Industrial Development and Investment corporation Ltd (RIICO) with 49% equity share holding. Rajasthan Drugs and Pharmaceuticals ltd.(RDPL) was incorporated on 02.11.1978 with the objective to supply life saving and other essential drugs.

Bhat Bio-tech India Private Limited is specialized in the design development, manufacture and marketing of diagnostic products and Biotechnology based products.

Post: Marketing Representative-(Life Sciences)

About Author:
Shambhavi Singh
B.Pharm (IV) School of Pharmaceutical Science,
Jaipur national university, Jaipur(RAJ.)
*shambhavisingh3111@gmail.com

Abstract
Broad-spectrum antibiotics are prescribed in one third patients for urinary tract infection, and use of third-generation cephalosporins has doubled in the past decade.
Bacteria in pregnancy frequently produce the risk of pyelonephritis, preterm labour, and low birth weight infants. Commonly prescribed antibiotics such as ampicillin (pivampicillin), amoxicillin, fluroqunin, trimethoprim, and sulphonamide are currently associated with development of a high degree of resistance towards most common pathogen responsible for causing urinary tract infection, Escherichia coli. During the past few decades new researches have been made against development of resistance in antibiotic and new drugs are synthesised. The presumption that if a specific drug is safe for the both pregnant woman and the foetus depends on how widely the drug has been used. A recent survey among general practitioners and obstetricians in confirmed that the beta-lactam antibiotic pivmecillinam and ciphalosporins are the most commonly used agents in the treatment of bacteriuria in pregnancy However, a surprisingly high number of physicians reported that they prescribe TMP/SMX during the first two trimesters in spite of resistance of E. coli and possible adverse effects on the foetus.

EPIDermizz, a skincare division of Nippon Seiyaku Pvt. Ltd. Nippon Seiyaku Pvt. Ltd. is an associate of Nippon Seiyaku co. Ltd., Japan which have been started its operation in Indian Market in 2001. Having robust brand NUTRIFACTS, Nippon is one of the most admired companies in pediatric fraternity. It has the history of pioneering in the area of nutrition by launching molecules like Methylcobalamine, Benfothiamine and Co Enzyme Q10 first time in India.

NIMS Institute of Pharmacy is approved by AICTE (All India Council for technical Education), Government of India. It offers undergraduate, postgraduate and Ph. D. programmes. The Institute has its separate building in the campus with spacious well equipped laboratories for each discipline and specialization. Pharma D. course has been designed on the lines of some universities in USA.

Pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.

Post: MR/MT

Birla Institute of

About Authors:
Piyush Gupta*
Department of Pharmaceutics,
Regional College of Pharmacy,
Jaipur, Rajasthan

ABSTRACT:-
The term MICROSPHERE is defined as a spherical particle with size varying from 50nm to 2µm, containing a core substance. Microspheres are, in strict sense, spherical empty particles.However, the terms microspheres and microencapsulationare used synonymously. In addition, some related terms are “beads” are used alternatively. Spheres and spherical particles are also usedfor a large size and rigid morphology. The microspheres are characteristically free flowing powders consisting of proteins orsynthetic polymers, which are biodegradable in nature, andideally having a particle size less than 200 micrometer. Novel Drug Delivery Systems are developed to address the challengesof drug development such as Bioavailability, Permeability & Poor solubility. These demand changes in the conventional use of Excipients, the growth of the Biotechnology industry,including Stem cell therapy,Vaccines & Genetic products, also necessitates different drug delivery requirements, there by demonstrating the acceptance of these excipients by the US food & drug administration or other agencies in the major markets.For materials in which Toxicity is a possible concern, formulators can give information about the excipients regulatory acceptance& allowable amount by consulting with excipients manufactures& toxicology experts.